Drug Profile
SP 2078
Alternative Names: SP-2078Latest Information Update: 31 Aug 2023
Price :
$50
*
At a glance
- Originator Seachaid Pharmaceuticals
- Class Antibacterials; Glycopeptides
- Mechanism of Action Cell wall inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Gram-positive infections
Most Recent Events
- 31 Aug 2023 Preclinical development in Gram-positive infections is ongoing in USA (Seachaid Pharmaceuticals pipeline, August 2023)
- 28 May 2020 No recent reports of development identified for preclinical development in Gram-positive-infections in USA
- 21 Apr 2016 Preclinical trials in Gram-positive infections in USA (unspecified route)